The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Celldex Therapeutics Inc. shares valued at $1,045,962 were sold by Crowley Elizabeth on Jun 14 ’24. At $34.87 per share, Crowley Elizabeth sold 30,000 shares. The insider’s holdings dropped to 9,074 shares worth approximately $0.31 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Martin Samuel Bates sold 17,172 shares, netting a total of over 608,315 in proceeds. Following the sale of shares at $35.42 each, the insider now holds 28,125 shares.
Before that, Young Diane C. had sold 45,000 shares from its account. In a trade valued at $1,586,844, the SVP, CHIEF MEDICAL OFFICER traded Celldex Therapeutics Inc. shares for $35.26 each. Upon closing the transaction, the insider’s holdings decreased to 45,000 shares, worth approximately $73305.9.
As published in their initiating research note from Stifel on June 18, 2024, Celldex Therapeutics Inc. [CLDX] has been a Buy and the price target has been revised to $58. Analysts at Wolfe Research started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid June. As of December 20, 2023, TD Cowen has initiated its “an Outperform” rating for CLDX. Earlier on November 10, 2023, Wells Fargo upgraded its rating. Their new recommendation was “an Equal weight” for CLDX stock which previously was a “an Underweight”.
Analyzing CLDX Stock Performance
During the last five days, there has been a drop of approximately -2.56%. Over the course of the year, Celldex Therapeutics Inc. shares have dropped approximately -12.61%. Shares of the company reached a 52-week high of $53.18 on 03/04/24 and a 52-week low of $32.25 on 06/04/24. A 50-day SMA is recorded $37.62, while a 200-day SMA reached $35.14. Nevertheless, trading volume fell to 0.58 million shares from 0.6 million shares the previous day.
Support And Resistance Levels for Celldex Therapeutics Inc. (CLDX)
According to the 24-hour chart, there is a support level at 33.98, which, if violated, would cause prices to drop to 33.29. In the upper region, resistance lies at 35.80. The next price resistance is at 36.93. RSI (Relative Strength Index) is 42.62 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.22, which suggests the price will decrease in the coming days. Percent R is at 53.74%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
